Acceleron Pharma earned strong acclaim as an exceptional, science-driven biopharmaceutical employer centered on groundbreaking rare disease and oncology research before being acquired by Merck. Employee reviews consistently highlighted a collaborative, highly intelligent corporate culture, robust scientific talent, and competitive compensation packages including equity grants. Workplace experiences centered heavily on empowering clinical researchers to advance innovative therapeutics through complex clinical pipelines.
Acceleron Pharma was officially acquired by Merck and Company, a major global healthcare and pharmaceutical leader, in a definitive all-cash transaction valued at approximately $11.5 billion.
Acceleron Pharma was a prominent clinical-stage biopharmaceutical enterprise focused on discovering, developing, and commercializing novel protein therapeutics targeted at treating serious and rare diseases, particularly focusing on pulmonary and hem...